title: 18F-FDG PET for the identification of adrenocortical carcinomas among indeterminate adrenal tumors at computed tomography scanning.
abstract: BACKGROUND
  18F-fluorodeoxyglucose positron emission tomography (18F-FDG PET) has been proposed for the evaluation of adrenal tumors. However, only scarce data are available to evaluate its usefulness for the identification of primary adrenal carcinomas in patients with no previous history of cancer and equivocal tumors on computed tomography (CT) scan. The objective of the present study was to evaluate the diagnostic performance of 18F-FDG-PET to predict malignancy in such patients.
  
  
  METHODS
  This was a retrospective study carried out from 2006 to 2009 in a single university hospital center. Twenty-three consecutive patients without previous history of cancer investigated for adrenal tumors without features of benign adrenocortical adenoma on CT scan but no obvious ACC underwent 18F-FDG PET. All patients underwent adrenalectomy because of CT scan characteristics regardless of the results of 18F-FDG PET. The ratio of maxSUV adrenal tumor on maxSUV liver (adrenal/liver maxSUV ratio) during 18F-FDG PET was compared to Weiss pathological criteria.
  
  
  RESULTS
  Seventeen patients had an adrenal adenoma, 2 had small size adrenal carcinomas (<5 cm), 1 had an angiosarcoma, and 3 had noncortical benign lesions. An adrenal/liver maxSUV ratio above 1.6 provided 100% sensitivity, 90% specificity, and 100% negative predictive value for the diagnosis of malignant tumor.
  
  
  CONCLUSIONS
  Because of its excellent negative predictive value, 18F-FDG-PET may be of help in avoiding unnecessary surgery in patients with non-secreting equivocal tumors at CT scanning and low 18F-FGD uptake.
authors.affiliation: Department of Endocrinology, Centre Hospitalier Universitaire de Bordeaux, Hopital Haut Leveque, avenue de Magellan, 33604, Pessac, France. marie-laure.nunes@chu-bordeaux.fr
authors.forename: Marie Laure
authors.initials: ML
authors.lastname: Nunes
authors.forename: Alexandre
authors.initials: A
authors.lastname: Rault
authors.forename: Julie
authors.initials: J
authors.lastname: Teynie
authors.forename: Nathalie
authors.initials: N
authors.lastname: Valli
authors.forename: Martine
authors.initials: M
authors.lastname: Guyot
authors.forename: Delphine
authors.initials: D
authors.lastname: Gaye
authors.forename: Genevieve
authors.initials: G
authors.lastname: Belleannee
authors.forename: Antoine
authors.initials: A
authors.lastname: Tabarin
mesh_terms: D000306:Adrenal Cortex Neoplasms / Q000000981:diagnostic imaging*; D000310:Adrenal Gland Neoplasms / Q000000981:diagnostic imaging*; D018246:Adrenocortical Adenoma / Q000000981:diagnostic imaging; D000328:Adult; D000368:Aged; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008297:Male; D008875:Middle Aged; D049268:Positron-Emission Tomography; D019275:Radiopharmaceuticals; D012189:Retrospective Studies; D012680:Sensitivity and Specificity; D014057:Tomography, X-Ray Computed
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18
references.citation: J Clin Endocrinol Metab. 2005 Feb;90(2):871-7
references.pmid: 15572420
references.citation: Radiology. 2006 Mar;238(3):970-7
references.pmid: 16505394
references.citation: J Nucl Med. 2001 Jun;42(6):884-92
references.pmid: 11390552
references.citation: Cancer. 2009 Jan 15;115(2):243-50
references.pmid: 19025987
references.citation: Radiology. 2005 Feb;234(2):479-85
references.pmid: 15671003
references.citation: J Clin Endocrinol Metab. 2009 May;94(5):1713-22
references.pmid: 19190108
references.citation: Eur J Nucl Med Mol Imaging. 2008 Nov;35(11):2018-25
references.pmid: 18566816
references.citation: Int J Clin Pract. 2007 May;61(5):802-9
references.pmid: 17343665
references.citation: J Clin Endocrinol Metab. 2006 Jul;91(7):2650-5
references.pmid: 16670169
references.citation: J Clin Endocrinol Metab. 2000 Feb;85(2):637-44
references.pmid: 10690869